DBD
Diebold Nixdorf, Incorporated
DBD has lower modeled downside risk, despite its lower overall score.
INTC
Intel Corporation
INTC has the edge over DBD overall, supported by stronger fundamentals and stronger valuation.
DBD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
DBD's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
INTC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Healthy |
INTC's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
DBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $1.54 | -97% |
| Forward | 9.8x | $54.75 | — |
| Fair | 22x | $44.94 | -18% |
| Current | 26x | $54.75 | — |
| Expensive | 32x | $67.83 | +24% |
Historical ranges are pointers, not guarantees.
DBD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
INTC PE Valuation
INTC has no meaningful PE right now: it lost money over the past year.
DBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DBD's earnings to grow and its profitability to improve, with its revenue holding steady.
INTC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Broad | |
| Low |
INTC has the edge over DBD on the outlook, with more favorable revenue expectations.
DBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.56 | +166% |
| Q3 2026 | $2.09 | +53% |
| Q2 2026 | $3.01 | +$3.35 |
| Q1 2026 | $2.90 | +$3.17 |
| Q4 2025 | $2.54 | +$2.98 |
| Q3 2025 | $1.37 | +$1.37 |
| Q2 2025 | -$0.34 | -101% |
| Q1 2025 | -$0.27 | -101% |
| Q4 2024 | -$0.44 | -101% |
DBD has the edge over INTC on earnings quality, reporting a profit while its opponent remains loss making.
INTC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.41 | — |
| Q3 2026 | -$2.39 | -24000% |
| Q2 2026 | -$2.09 | +$2.68 |
| Q1 2026 | -$0.60 | +$3.88 |
| Q4 2025 | -$0.06 | +$4.32 |
| Q3 2025 | $0.01 | +$3.72 |
| Q2 2025 | -$4.77 | -2088% |
| Q1 2025 | -$4.48 | -562% |
| Q4 2024 | -$4.38 | -1195% |
INTC has swung to a loss: it lost $2.39 per share over the past year, after a profit the year before.
DBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $994.3M | +5.2% |
| Q2 2026 | $930.8M | +1.7% |
| Q1 2026 | $891.8M | +6% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $945.2M | +2% |
| Q2 2025 | $915.2M | -2.6% |
| Q1 2025 | $841.1M | -6.1% |
| Q4 2024 | $988.9M | -4.6% |
DBD has the edge over INTC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | -3.9 points |
| Q2 2026 | 6.2% | 0 points |
| Q1 2026 | 3.7% | +0.1 points |
| Q4 2025 | 7.5% | +3.3 points |
| Q3 2025 | 7.8% | +2.8 points |
| Q2 2025 | 6.1% | -1.4 points |
| Q1 2025 | 3.5% | +0.9 points |
| Q4 2024 | 4.2% | -1.2 points |
DBD's operating margin was 3.9% last quarter, down 3.9 points from the same quarter a year ago.
INTC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $16.5B | +21% |
| Q2 2026 | $16.1B | +25% |
| Q1 2026 | $13.6B | +7.2% |
| Q4 2025 | $13.7B | -4.1% |
| Q3 2025 | $13.7B | +2.8% |
| Q2 2025 | $12.9B | +0.2% |
| Q1 2025 | $12.7B | -0.4% |
| Q4 2024 | $14.3B | -7.4% |
INTC's revenue is recovering but still below its 2021 peak: $16.5B last quarter, up 21% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +10 points |
| Q2 2026 | 11% | +36 points |
| Q1 2026 | -23% | -21 points |
| Q4 2025 | 4.2% | +1.4 points |
| Q3 2025 | 5% | +73 points |
| Q2 2025 | -25% | -9.4 points |
| Q1 2025 | -2.4% | +6 points |
| Q4 2024 | 2.9% | -14 points |
INTC has the edge over DBD on profitability, with a higher operating margin.
DBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.4M | -227% |
| Q2 2026 | -$13.6M | -145% |
| Q1 2026 | $31.7M | +102% |
| Q4 2025 | $217.5M | +11% |
| Q3 2025 | $37.4M | +$52.9M |
| Q2 2025 | $30.1M | +$38.1M |
| Q1 2025 | $15.7M | +$39.2M |
| Q4 2024 | $196.2M | +26% |
DBD has burned cash in most quarters: $188M over the past year, down 33% from the year before.
INTC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +774% |
| Q2 2026 | $4.5B | +$6B |
| Q1 2026 | -$2.5B | +$1.8B |
| Q4 2025 | $800M | +$3.5B |
| Q3 2025 | $121M | +$2.5B |
| Q2 2025 | -$1.5B | +$1.9B |
| Q1 2025 | -$4.4B | +$2.8B |
| Q4 2024 | -$2.7B | -$597M |
INTC has the edge over DBD on cash flow, with more consistent year-over-year improvement.
DBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -700K shares |
| 1 year | -6.5% | -2.4M shares |
| 3 years | -7.9% | -3M shares |
| 5 years | -56% | -43.7M shares |
| Available history | -55% | -42.2M shares |
DBD has the edge over INTC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $33.9M |
| Q2 2026 | $60.6M |
| Q1 2026 | $60.4M |
| Q4 2025 | $51.1M |
| Q3 2025 | $39.9M |
| Q2 2025 | $30.1M |
| Q1 2025 | $9.6M |
| Q4 2024 | $2.3M |
DBD spent $206M buying back its own shares over the past year, up 152% from the year before.
INTC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4% | +203M shares |
| 1 year | +17% | +776M shares |
| 3 years | +25% | +1.1B shares |
| 5 years | +30% | +1.2B shares |
| Available history | +19% | +834M shares |
INTC has 5.3B diluted shares, up 17% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | $114M |
| Q1 2021 | $2.3B |
DBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.8x | Moderate |
DBD's net debt is about 2.3 years of its operating earnings (EBITDA), about the same as a year ago.
INTC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.0x | Healthy |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.9x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.0x | Elevated |
| Q1 2025 | 69.6x | High |
| Q3 2024 | 23.8x | High |
| Q2 2024 | 4.3x | High |
INTC has the edge over DBD on leverage, with a lower net debt burden relative to earnings.
DBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 11.4 | Oversold |
DBD's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
INTC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 7.7 | Oversold |
INTC's weekly RSI is 38 (neutral) and its Stochastic is 8 (oversold).
DBD PE vs Technology Sector
| Metric | DBD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 28x | 6% below |
| PE % | 61 | 25 | 36 pts above |
DBD is trading at 26x earnings, in line with the Technology sector's median of 28x.
INTC PE vs Technology Sector
| Metric | INTC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
INTC has no meaningful PE right now: it lost money over the past year.
DBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.8 | 11% below |
| 20 week MA | $69.7 | 21% below |
| 50 week MA | $73.3 | 25% below |
| 100 week MA | $62.4 | 12% below |
INTC has stronger trend alignment. DBD is above 0 of 4 weekly averages versus INTC above 2 of 5.
INTC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.4 | 31% below |
| 20 week MA | $95.3 | 36% below |
| 50 week MA | $79.3 | 23% below |
| 100 week MA | $52.1 | 18% above |
| 200 week MA | $42.5 | 44% above |
INTC has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 44% above its 200-week average.
DBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $20.1 | $29.0 | +44% |
| 2024 | $29.0 | $42.9 | +48% |
| 2025 | $42.9 | $69.3 | +61% |
| 2026 YTD | $69.3 | $54.8 | -21% |
DBD has finished every year since 2023 higher, and it's down 21% so far in 2026.
INTC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $60.1 | $47.1 | -22% |
| 2021 | $47.1 | $51.3 | +9% |
| 2022 | $51.3 | $26.1 | -49% |
| 2023 | $26.1 | $50.3 | +93% |
| 2024 | $50.3 | $20.3 | -60% |
| 2025 | $20.3 | $36.2 | +78% |
| 2026 YTD | $36.2 | $61.2 | +69% |
INTC has the edge over DBD on returns for 2026, with the stronger performance.